Multicentre European study for the treatment of advanced emphysema with bronchial valves

This multicentre, blinded, sham-controlled study was performed to assess the safety and effectiveness of bronchial valve therapy using a bilateral upper lobe treatment approach without the goal of lobar atelectasis. Patients with upper lobe predominant severe emphysema were randomised to bronchoscopy with (n=37) or without (n=36) IBV Valves for a 3-month blinded phase. A positive responder was defined as having both a ≥4-point improvement in St George’s Respiratory Questionnaire (SGRQ) and a lobar volume shift as measured by quantitative computed tomography. At 3 months, there were eight (24%) positive responders in the treated group versus none (0%) in the control group (p=0.002). Also, there was a significant shift in volume in the treated group from the upper lobes (mean±sd -7.3±9.0%) to the non-treated lobes (6.7±14.5%), with minimal change in the control group (p<0.05). Mean SGRQ total score improved in both groups (treatment: -4.3±16.2; control: -3.6±10.7). The procedure and devices were well tolerated and there were no differences in adverse events reported in the treatment and control groups. Treatment with bronchial valves without complete lobar occlusion in both upper lobes was safe, but not effective in the majority of patients.

[1]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[2]  D. Hansell,et al.  Atelectasis and survival after bronchoscopic lung volume reduction for COPD , 2010, European Respiratory Journal.

[3]  G. McLennan,et al.  A randomized study of endobronchial valves for advanced emphysema. , 2010, The New England journal of medicine.

[4]  M. Wahidi,et al.  Interventional Pulmonology a Multicenter Pilot Study of a Bronchial Valve for the Treatment of Severe Emphysema for Editorial Comment See P. 191 Severe Emphysema Treated with Bronchial Valves , 2022 .

[5]  D. Wood,et al.  Treatment of heterogeneous emphysema using the spiration IBV valves. , 2009, Thoracic surgery clinics.

[6]  S. Cogswell,et al.  Computed tomography assessment of lung volume changes after bronchial valve treatment , 2008, European Respiratory Journal.

[7]  J. Reilly.  COPD and declining FEV1--time to divide and conquer? , 2008, The New England journal of medicine.

[8]  M. Decramer,et al.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.

[9]  Marco Ranucci,et al.  A Meta-analysis of Randomized Clinical Trials , 2008 .

[10]  K. Naunheim.  Lung-volume reduction surgery: a vanishing operation? , 2007, The Journal of thoracic and cardiovascular surgery.

[11]  M. Noppen.  Collateral Ventilation in End-Stage Emphysema: A Blessing or a Curse for New Bronchoscopic Treatment Approaches (or Both)? , 2007, Respiration.

[12]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[13]  T. Gildea,et al.  A multicenter trial of an intrabronchial valve for treatment of severe emphysema. , 2007, Journal of Thoracic and Cardiovascular Surgery.

[14]  D. Mannino,et al.  Global burden of COPD: systematic review and meta-analysis , 2006, European Respiratory Journal.

[15]  F. Martinez,et al.  Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. , 2006, The Annals of thoracic surgery.

[16]  D. Hansell,et al.  Effect of bronchoscopic lung volume reduction on dynamic hyperinflation and exercise in emphysema. , 2005, American journal of respiratory and critical care medicine.

[17]  F. Venuta,et al.  Bronchoscopic lung-volume reduction with one-way valves in patients with heterogenous emphysema. , 2005, The Annals of thoracic surgery.

[18]  Edward P Ingenito,et al.  Lung volume reduction surgery: a meta-analysis of randomized clinical trials. , 2005, Treatments in respiratory medicine.

[19]  W. MacNee,et al.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.

[20]  D. Hansell,et al.  Bronchoscopic volume reduction with valve implants in patients with severe emphysema. , 2003, The Lancet.

[21]  R. Pauwels,et al.  Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial , 2003, The Lancet.

[22]  P. Jones.  Interpreting thresholds for a clinically significant change in health status in asthma and COPD , 2002, European Respiratory Journal.

[23]  P. Jones,et al.  Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease , 1999, Thorax.

[24]  Carol A. Trujillo,et al.  The MOS 36-Item Short Form Health Survey: reliability, validity, and preliminary findings in schizophrenic outpatients. , 1998, Medical care.

[25]  A. Fein.  Lung volume reduction surgery: answering the crucial questions. , 1998, Chest.

[26]  G. Patterson,et al.  Results of 150 consecutive bilateral lung volume reduction procedures in patients with severe emphysema. , 1996, The Journal of thoracic and cardiovascular surgery.

[27]  C. McHorney,et al.  The MOS 36‐Item Short‐Form Health Survey (SF‐36): II. Psychometric and Clinical Tests of Validity in Measuring Physical and Mental Health Constructs , 1993, Medical care.

[28]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[29]  P. Jones,et al.  The St George's Respiratory Questionnaire. , 1991, Respiratory medicine.

[30]  P. Enright,et al.  Effect of effort on measurement of forced expiratory volume in one second. , 1987, The American review of respiratory disease.